Clinical Trials Logo

Carcinoma, Large Cell clinical trials

View clinical trials related to Carcinoma, Large Cell.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01441128 Terminated - Adenocarcinoma Clinical Trials

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer

Start date: September 1, 2011
Phase: Phase 1
Study type: Interventional

Background: - PF-02341066 and PF-00299804 are drugs that specifically target certain proteins that may be more active in cancer cells than normal cells, in particular in non-small cell lung cancer. Both drugs seem to be able to stop the growth of or kill cancer cells. Researchers want to combine them to see if they are a safe and effective treatment for advanced non-small cell lung cancer. Objectives: - To test the safety and effectiveness of PF-02341066 and PF-00299804 for advanced non-small cell lung cancer. Eligibility: - Individuals at least 18 years of age with advanced non-small cell lung cancer that has not responded to standard treatments. Design: - Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, and imaging studies. Heart and lung function tests and an eye exam may also be given. - The first cycle of treatment will be 28 days. Every cycle after the first will be 21 days. Participants may have up to 17 cycles of treatment. - Participants will take both study drugs as tablets. Twelve hours after the first dose, participants will take only the PF-02341066. This dose schedule will remain the same throughout the study. - Participants will be monitored with frequent blood and urine tests and imaging studies. Tumor biopsies will be taken as needed. Those in the study will keep a diary to record any symptoms or side effects of taking the study drugs. - After 17 cycles of treatment, or after stopping the study drugs early for any other reason, participants will have a final followup visit.

NCT ID: NCT00673049 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

NSCLC
Start date: May 2008
Phase: Phase 3
Study type: Interventional

The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).

NCT ID: NCT00632203 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The main objective of this study is to investigate whether administration of maintenance temozolomide following standard treatment could possibly prevent or delay the onset of brain metastases in patients with controlled non-small cell lung cancer (NSCLC).

NCT ID: NCT00596830 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Start date: April 2008
Phase: Phase 3
Study type: Interventional

Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.